UCB SA (EBR:UCB)

Market Cap	43.43B
Revenue (ttm)	6.85B
Net Income (ttm)	1.33B
Shares Out	190.00M
EPS (ttm)	6.87
PE Ratio	33.29
Forward PE	25.56
Dividend	1.39 (0.61%)
Ex-Dividend Date	Apr 25, 2025

Volume	242,816
Average Volume	343,345
Open	226.50
Previous Close	226.90
Day's Range	224.80 - 228.90
52-Week Range	129.35 - 263.20
Beta	0.22
RSI	48.60
Earnings Date	Feb 26, 2026

About UCB SA

UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases worldwide. The company’s primary products include Cimzia for inflammatory TNF-mediated diseases, as well as ankylosing spondylitis (AS), axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; Vimpat, Keppra, and Briviact for epilepsy; and Neupro for Parkinson’s disease and restless legs syndrome. It also provides Nayzilam, a nasal spra...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1925
• Employees: 9,378
• Stock Exchange: Euronext Brussels
• Ticker Symbol: UCB

Financial Performance

In 2024, UCB SA's revenue was 6.15 billion, an increase of 18.72% compared to the previous year's 5.18 billion. Earnings were 1.07 billion, an increase of 210.50%.